Respiratory Inhaler Devices Market Snapshot (2023 to 2033)

The global respiratory inhaler devices market size is anticipated to attain an impressive valuation of USD 37,258.5 million in 2023 and is projected to reach USD 60,114.7 million by 2033, trailing a CAGR of 4.90% during the forecast period.

The rising prevalence of respiratory disorders across the globe is driving the growth in the respiratory inhaler device market. The surging demand for treatment options for respiratory disorders and access to well-developed technologies are further expected to the product demand.

In addition, the ever-increasing elderly population, growing awareness regarding pulmonary diseases and rise in healthcare expenditure are sculpting growth in the market. Moreover, the rise in air pollution level throughout the globe is fuelling the product demand.

Growing cases of forest fire, increasing number of automobiles and growing number of factories are fostering growth in the market. Furthermore, rising use of fluoroscopy in pain management caused due to respiratory disorders will boost the product sales.

The rapid technological advancements along with several initiatives undertaken by governments to stop respiratory diseases will open up new avenues for market expansion. The growth will be driven by spreading awareness regarding the symptoms of respiratory disorders and availability of new treatment.

Report Attribute Details
Expected Market Value (2023) USD 37,258.5 million
Anticipated Forecast Value (2033) USD 60,114.7 million
Projected Growth Rate (2023 to 2033) CAGR 4.90%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Respiratory Inhalers Devices Demand Analysis vs. Forecast 2023 to 2033

The market for respiratory inhaler devices was worth USD 30,556.81 million in 2018, while growing at a CAGR of 3.95% during the historical period.

Over the years, metered dose inhalers are increasingly being adopted for the treatment of various respiratory disorders like asthma and COPD. The ability of these inhalers to deliver the right amount of medication fast is helping the market to grow. Various governments in developed nations are also supporting the production of tech superior inhaler devices due to their massive demand among the populace. Both of these factors will positively affect the market growth in the coming years.

Also, the demand for respiratory inhalers is expected to witness an upswing in the coming years. There is rapid surge in demand for dry powder inhalers’s due to prevalence of emphysema, bronchitis, and other disorders etc.. The presence of these disorders amongst teenagers and adults is pushing the pharmaceutical companies to work on research and development to innovative new formulation technologies.

The advancements in technology is further expected to drive the market growth. Rise in advancements in the advance portable inhalation technology will aid the market growth.

The expansion of healthcare sector's and its ability to deliver affordable drugs is providing a strong stimulus for market expansion. Increasing government effors to provide affordable and accessible medicine is a significant factor that will contribute to market growth in the next ten years.

Considering these factors and new developments, the revenue growth of respiratory inhalers devices market is projected to be worth USD 60114.7 million by end of the forecast period, while exhibiting a CAGR of 4.90 %.

Which are Some Prominent Drivers spearheading the Respiratory Inhalers devices market?

Adoption of Combination therapies to drive market growth

The growing prevalence of respiratory diseases such as COPD, emphysema and asthma, are driving the demand for respiratory inhalers. The burgeoning necessity for rescue medication during sudden asthma attack; and escalating demand for short-term and effective medication are leading to market expansion.

Along with this, rising focus of companies toward the development of advanced and portable inhalation devices will provide a breeding ground for the market expansion. Further, government initiatives toward spreading awareness for COPD and asthma symptoms are anticipated to augment the product sales.

The increasing adoption of combination therapies for asthma is further propeling the demand for respiratory inhalers, like dry powder inhalers and soft mist inhalers due to their effective results on the patients. These devices are proving to become best options to induce the combination drug.

On the other hand, use of smart inhaler technology is expected to drive market growth. Employing smart inhaler devices that are more intuitive and that drive the patient engagement while enhancing treatment effectiveness will further amplify the product sales.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the challenges Projected to be Faced by the Market?

High cost of Inhalation devices to restrict product sales

Factors such as rising environmental concerns associated with metered dose inhalers (MDI) along with the high cost of some inhalation devices and treatment will most likely restrain the market growth.

Also, growing competition among product prices, and deterioration of product quality are further expected to hamper the market growth. Further, incompetent reimbursement support and expiration of patents for blockbuster drugs will be some other roadblocks that may restrict the market growth.

Region-Wise Insights

What are the growth prospects in North America?

North America to dominate the market with maximum share

North America dominate the respiratory inhalers device market by accumulating 41.40% market share in 2022. The region is expected to retain its lead by accounting for over 45% market share by end of the forecast period. The growth is attributed to widespread and early adoption of inhalers and nebulizers along with large pool of patients suffering from respiratory ailments.

Also, increasing awareness about proactive asthma management in children in this region will further drive the market growth. The United States alone accounted for 37.10% revenue share in 2022 and is expected to lead the region by accumulating over 47% market share by end of the forecast period.

According to the National Institute of Health, in 2021, the USA population aged over 65 years is expected to double over the next thirty years, from 48 million in 2015 to more than 88 million by 2050.

Also, According to the Asthma and Allergy Foundation of America (AAFA), on an average, 11 people in the USA die from asthma every day. It further stated that in 2020, 4,145 people were deceased due to asthma. Almost all of these deaths could have been prevented with the proper treatment by utilizing respiratory inhalers.

In 2020, Asthma-related deaths increased for the first time in 20 years, According to the Illinois Department of Central Management Services in 2022, annual costs incurred per patient in the USA is over USD 3,000. Due to high mortality rate associated with asthma and rising investment in asthma treatment in this country, the market is anticipated to reflect significant growth in the coming years.

What is the growth outlook in China?

Increasing Air Pollution and associated Lung Disorders driving growth

The market in China is expected to grow with a significant CAGR of 5.20% during the forecast period. Rising air pollution in the region is leading to chronic respiratory diseases among people, which is directly fuelling the demand for respiratory inhaler devices.

Also, increasing use of combination therapies in respiratory devices and mounting investment by key industry players to innovate advanced respiratory inhaler devices will further foster growth in the region.

The rapidly expanding healthcare infrastructure is opening up new avenues for the market expansion. This region also has highest patients suffering from respiratory ailments which will help in keeping the product demand stable in the coming years.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category wise Insights

By Product Type, which segment will experience Maximum Uptake?

Metered dose inhalers to account for maximum market share

The metered dose inhaler segment accounted for a dominating share of 71.20 % in 2022. It is expected to continue its trend of dominance by commanding over 75.4% share by 2033.

The inhalation route is fast acting and most effective way of delivering medications to the respiratory system during treatment of asthma and COPD. This is expected to keep the metered dose inhalers in demand through the forecast period.

By disease indication, which segment is expected to dominate the market?

Asthma to remain at the top in terms of market share

Asthma segment registered maximum share of 60% in 2022 in terms of disease indication. This segment is poised to contribute highest share of 66.8 % by end of the forecast period.

The rising prevalence of asthma across the globe is helping in the segments growth. Further, increasing activities by government organizations and NGOs in spreading awareness and increasing research and development activities in developing asthma device technologies, are some factors expected to fuel the segments growth.

For example, in March 2022, the United stated food and drug administration granted approval for the use of first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for treating two common pulmonary health conditions, including asthma in patients above six years of age. This development will boost the growth of the segment.

Start-ups in Respiratory Inhaler Devices Market

Start-ups help in determining the future growth opportunities in any market. These new entrants have the potential to generate high returns which directly benefits the expansion of any industry. These start-ups are typically more efficient at transforming inputs into outputs with more flexibility and adaptability in nature, able to shift quickly in response to sensitive market conditions. Some of the start-ups that will fuel the expansion of Respiratory Inhalers devices market are:

  • ‘BreatheSuite’ is a St.Johns, Canada-based startup firm that was founded in 2018. It has developed an integrated inhaler device for medication adherence to manage COPD and asthma. This device is connected to an app via Bluetooth to monitor the intake and dosage of medicine. The inhaler is used to monitor the technique. This app also provides real-time training. The app also notifies the user to take the medicine. The app can be to conncect with physicians, care teams and family members to share the medication data for managing the respiratory disease.
  • MicroVapor Devices has created Pocket Neb, a lightweight, portable vibrating mesh nebulizer for aerosol drug delivery to patients with respiratory ailements like asthma and COPD. It has over 4,000 micro holes that allow 98% delivery of soluble medications. The company has received FDA clearance for its device. It is a Columbia, USA-based company. It was founded in 2018.
  • CareTRx is a mobile app and sensor offered by Gecko Health for the management of asthma. The device is added to pre-existing inhalers. It aims at assiting patients to better manage their asthma by tracking medication use, giving reminders and increasing awareness toward the disease. The offering involves a direct sensor monitoring, games and analytical features. It also uses gamification via AirQuest App to act as a reminder to use an inhaler.

Market Competition

The Respiratory Inhalers devices market is extremely competitive and consists of numerous key industry players. These players are innovating novel delivery systems for treating respiratory disease. This is expected to propel Respiratory Inhalers devices market. The key industry players are:

  • AstraZeneca
  • Beximco Pharmaceuticals Ltd.
  • Boehringer Ingelheim GmbH
  • Cipla Ltd.
  • GlaxoSmithKline plc.
  • Koninklijke Philips N.V.
  • Merck & Co., Inc.
  • OMRON Healthcare Europe B.V.
  • PARI Medical Holding
  • Teva Pharmaceutical Industries Ltd.

Some recent developments in the market are:

Key market players are leveraging on inorganic growth strategies like acquisition, mergers, partnerships, and collaboration in order to enhance their product portfolio. This is expected to fuel the global Respiratory Inhalers devices market.

  • In December 2020, OMRON Healthcare introduced WheezeScan for children suffering from Asthma to accurately detect the presence of wheezing in young children and to remove the unpredictability of potential misdiagnosis.
  • In March 2021, in the United States and Mexico, AstraZeneca PLC initiated a Phase III clinical trial to assess the effectiveness and safety of budesonide/glycopyrronium/formoterol inhalers in adolescents and adults with chronic asthma inadequately controlled with standard care. The will trial will be completed in September 2023.
  • In May 2022, Alkem intorduced its first inhalation device, Innohaler, for asthma and COPD and asthma patients.

Report Scope

Report Attribute Details
Market Value in 2023 USD  37,258.5 million
Market Value in 2033 USD 60,114.7 million
Growth Rate CAGR of 4.9% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered Product, Technology, Disease Indication, Region
Regions Covered North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa
Key Countries Profiled United States,  Canada,  Brazil,  Mexico,  Germany,  United Kingdom,  France,  Spain,  Italy,  India,  China,  Japan,  Malaysia,  Singapore,  Thailand,  South Korea,  Australia,  New Zealand,  GCC Countries,  South Africa,  Israel
Key Companies Profiled

AstraZeneca;   Beximco Pharmaceuticals Ltd.;   Boehringer Ingelheim GmbH;   Cipla Ltd.;   GlaxoSmithKline plc.;   Koninklijke Philips N.V.;   Merck & Co., Inc.;   OMRON Healthcare Europe B.V.;   PARI Medical Holding;   Teva Pharmaceutical Industries Ltd.

Customization Available Upon Request

Key Segments Profiled in the Respiratory Inhalers Devices Industry Survey

By Product:

  • Dry Powder Inhalers
  • Metered Dose Inhalers
  • Nebulizers
    • Compressed Air Nebulizers
    • Ultrasonic Nebulizers
    • Mesh Nebulizers

By Technology:

  • Manually Operated Inhaler Devices
  • Digitally Operated Inhaler Devices

By Disease Indication:

  • Asthma
  • Chronic Obstructive Pulmonary Disease
  • Pulmonary Arterial Hypertension
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East and Africa

Frequently Asked Questions

What is the Current Size of The Market?

In 2023, the market is expected to be around US$ 37,258.5 million.

How Much Did the Market's HCAGR Progress?

The market's sales increased at a HCAGR of 3.9% between 2018 and 2022.

How Much Market Growth is Anticipated at What CAGR?

The market is expected to endure at a 4.9% CAGR through 2033.

Which Product Type Segment Represents the Majority?

The metered dose inhaler sector may  capturing 75.4% of the market by 2033.

What is the Market's Estimation by 2033?

By 2033, the market is expected to be worth US$ 60,114.7 million.

Table of Content
	1. Executive Summary | Respiratory Inhaler Devices Market
	2. Market Overview
	3. Market Background
	4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
	5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product
		5.1. Dry Powder Inhalers
		5.2. Metered Dose Inhalers
		5.3. Nebulizers
			5.3.1. Compressed Air Nebulizers
			5.3.2. Ultrasonic Nebulizers
			5.3.3. Mesh Nebulizers
	6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Technology
		6.1. Manually Operated Inhaler Devices
		6.2. Digitally Operated Inhaler Devices
	7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Indication
		7.1. Asthma
		7.2. Chronic Obstructive Pulmonary Disease
		7.3. Pulmonary Arterial Hypertension
		7.4. Others
	8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
		8.1. North America
		8.2. Latin America
		8.3. Europe
		8.4. South Asia
		8.5. East Asia
		8.6. Oceania
		8.7. Middle East & Africa
	9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	15. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
	16. Key Countries Market Analysis
	17. Market Structure Analysis
	18. Competition Analysis
		18.1. AstraZeneca
		18.2. Beximco Pharmaceuticals Ltd.
		18.3. Boehringer Ingelheim GmbH
		18.4. Cipla Ltd.
		18.5. GlaxoSmithKline plc.
		18.6. Koninklijke Philips N.V.
		18.7. Merck & Co., Inc.
		18.8. OMRON Healthcare Europe B.V.
		18.9. PARI Medical Holding
		18.10. Teva Pharmaceutical Industries Ltd.
	19. Assumptions & Acronyms Used
	20. Research Methodology
Recommendations

Healthcare

Cold, Cough, and Sore Throat Remedy Market

April 2024

REP-GB-1292

250 pages

Healthcare

Throat Sprays Market

June 2023

REP-GB-15391

324 pages

Healthcare

Steroid-Free Nasal Sprays Market

June 2023

REP-GB-15127

225 pages

Healthcare

Strep Throat Treatment Market

March 2023

REP-GB-12169

250 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Respiratory Inhaler Devices Market

Schedule a Call